TY - JOUR
T1 - Decrypting the potential role of α-lipoic acid in Alzheimer's disease
AU - Kaur, Dapinder
AU - Behl, Tapan
AU - Sehgal, Aayush
AU - Singh, Sukhbir
AU - Sharma, Neelam
AU - Chigurupati, Sridevi
AU - Alhowail, Ahmed
AU - Abdeen, Ahmed
AU - Ibrahim, Samah F.
AU - Vargas-De-La-Cruz, Celia
AU - Sachdeva, Monika
AU - Bhatia, Saurabh
AU - Al-Harrasi, Ahmed
AU - Bungau, Simona
N1 - Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Alzheimer's disease (AD) is one of the most prevalent neurodegenerative diseases with motor disturbances, cognitive decline, and behavioral impairment. It is characterized by the extracellular aggregation of amyloid-β plaques and the intracellular accumulation of tau protein. AD patients show a cognitive decline, which has been associated with oxidative stress, as well as mitochondrial dysfunction. Alpha-lipoic acid (α-LA), a natural antioxidant present in food and used as a dietary supplement, has been considered a promising agent for the prevention or treatment of neurodegenerative disorders. Despite multiple preclinical studies indicating beneficial effects of α-LA in memory functioning, and pointing to its neuroprotective effects, to date only a few studies have examined its effects in humans. Studies performed in animal models of memory loss associated with aging and AD have shown that α-LA improves memory in a variety of behavioral paradigms. Furthermore, molecular mechanisms underlying α-LA effects have also been investigated. Accordingly, α-LA shows antioxidant, antiapoptotic, anti-inflammatory, glioprotective, metal chelating properties in both in vivo and in vitro studies. In addition, it has been shown that α-LA reverses age-associated loss of neurotransmitters and their receptors. The review article aimed at summarizing and discussing the main studies investigating the neuroprotective effects of α-LA on cognition as well as its molecular effects, to improve the understanding of the therapeutic potential of α-LA in patients suffering from neurodegenerative disorders, supporting the development of clinical trials with α-LA.
AB - Alzheimer's disease (AD) is one of the most prevalent neurodegenerative diseases with motor disturbances, cognitive decline, and behavioral impairment. It is characterized by the extracellular aggregation of amyloid-β plaques and the intracellular accumulation of tau protein. AD patients show a cognitive decline, which has been associated with oxidative stress, as well as mitochondrial dysfunction. Alpha-lipoic acid (α-LA), a natural antioxidant present in food and used as a dietary supplement, has been considered a promising agent for the prevention or treatment of neurodegenerative disorders. Despite multiple preclinical studies indicating beneficial effects of α-LA in memory functioning, and pointing to its neuroprotective effects, to date only a few studies have examined its effects in humans. Studies performed in animal models of memory loss associated with aging and AD have shown that α-LA improves memory in a variety of behavioral paradigms. Furthermore, molecular mechanisms underlying α-LA effects have also been investigated. Accordingly, α-LA shows antioxidant, antiapoptotic, anti-inflammatory, glioprotective, metal chelating properties in both in vivo and in vitro studies. In addition, it has been shown that α-LA reverses age-associated loss of neurotransmitters and their receptors. The review article aimed at summarizing and discussing the main studies investigating the neuroprotective effects of α-LA on cognition as well as its molecular effects, to improve the understanding of the therapeutic potential of α-LA in patients suffering from neurodegenerative disorders, supporting the development of clinical trials with α-LA.
KW - Alpha-lipoic acid
KW - Alzheimer's disease
KW - Anti-oxidants
KW - Mitochondrial dysfunction
KW - Oxidative stress
UR - http://www.scopus.com/inward/record.url?scp=85113760191&partnerID=8YFLogxK
U2 - 10.1016/j.lfs.2021.119899
DO - 10.1016/j.lfs.2021.119899
M3 - Artículo de revisión
AN - SCOPUS:85113760191
SN - 0024-3205
VL - 284
JO - Life Sciences
JF - Life Sciences
M1 - 119899
ER -